Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.75 |
| ▸ | NAT1 | P18440 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.64 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.62 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.58 |
| ▸ | MYC | P01106 | 1/20 | 0.57 |
| ▸ | MAX | P61244 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8309757 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1NAT1MEN1NPC1 | |
| SCHEMBL7768284 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1NAT1MEN1NPC1 | |
| SCHEMBL8535410 | 0.92 | PTGS2 (0.85) | PTGS2PTGS1NAT1MEN1NPC1 | |
| SCHEMBL8535412 | 0.92 | PTGS2 (0.85) | PTGS2PTGS1NAT1MEN1NPC1 | |
| SCHEMBL10519512 | 0.89 | PTGS2 (0.80) | PTGS2PTGS1NAT1MEN1NPC1 | |
| SCHEMBL8536872 | 0.87 | PTGS2 (0.76) | PTGS2PTGS1NAT1MEN1NPC1 | |
| SCHEMBL8536869 | 0.87 | PTGS2 (0.76) | PTGS2PTGS1NAT1MEN1NPC1 | |
| SCHEMBL8962138 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1NAT1GAACISD1 | |
| SCHEMBL3667218 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1NAT1GAACISD1 | |
| SCHEMBL3667216 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1NAT1GAACISD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8357701-B2 | Galactokinase inhibitors | UNIVERSITY OF MIAMI (US) | 2013-01-22 | — | — | US | disclosed |
| US-8357701-B2 | Galactokinase inhibitors | UNIVERSITY OF MIAMI (US) | 2013-01-22 | — | — | US | disclosed |
| US-20110251236-A1 | GALACTOKINASE INHIBITORS | UNIVERSITY OF MIAMI (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251236-A1 | GALACTOKINASE INHIBITORS | UNIVERSITY OF MIAMI (US) | 2011-10-13 | — | — | US | disclosed |
| US-5767121-A | ANTIINFLAMMATORY AND -ARTHRITIC AGENTS; ANTIPYRETICS; ANALGESICS; ADHESION PROTEIN EXPRESSION AND CYCLOXYGENASE AND 5-LIPOXYGENASE INHIBITORS; IMMUNOSUPPRESSANTS AND -MODULATORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-06-16 | — | — | US | disclosed |
| EP-0612729-B1 | Pyridine derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-04-23 | — | — | EP | disclosed |
| US-5561147-A | ANTIINFLAMMATORY AGENT, ANTIPYRETIC, ANALGESICS, ANTIALLERGENS, IMMUNOSUPPRESSANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-10-01 | — | — | US | disclosed |
| US-5457106-A | Antiinflammatory agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-10-10 | — | — | US | disclosed |
| US-5389658-A | Administering as antipyretic, antiinflammatory, analgesic, antiallergic, or immunosupressive agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-02-14 | — | — | US | disclosed |
| EP-0612729-A2 | Pyridine derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1994-08-31 | — | — | EP | disclosed |
| US-5246948-A | Antiinflammatory, antipyretic, analgesic, antiallergic, immunosupressing or immunomodulating activity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-09-21 | — | — | US | disclosed |
| EP-0522606-A2 | Pyridine derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251236-A1 | GALACTOKINASE INHIBITORS | GALK1, GALE, GALC | PTGS2 3336/4885PTGS1 2971/4885NAT1 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.